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Abstract
Background: Histone deacetylase inhibitors (HDACIs) induce hyperacetylation of core histones
modulating chromatin structure and affecting gene expression. These compounds are also able to
induce growth arrest, cell differentiation, and apoptotic cell death of tumor cells in vitro as well as
in vivo. Even though several genes modulated by HDAC inhibition have been identified, those genes
clearly responsible for the biological effects of these drugs have remained elusive. We investigated
the pharmacological effect of the HDACI and potential anti-cancer agent Trichostatin A (TSA) on
primary T cells.
Methods: To ascertain the effect of TSA on resting and activated T cells we used a model system
where an enriched cell population consisting of primary T-cells was stimulated in vitro with
immobilized anti-CD3/anti-CD28 antibodies whilst exposed to pharmacological concentrations of
Trichostatin A.
Results: We found that this drug causes a rapid decline in cytokine expression, accumulation of
cells in the G1 phase of the cell cycle, and induces apoptotic cell death. The mitochondrial
respiratory chain (MRC) plays a critical role in the apoptotic response to TSA, as dissipation of
mitochondrial membrane potential and reactive oxygen species (ROS) scavengers block TSA-
induced T-cell death. Treatment of T cells with TSA results in the altered expression of a subset
of genes involved in T cell responses, as assessed by microarray gene expression profiling. We also
observed up- as well as down-regulation of various costimulatory/adhesion molecules, such as
CD28 and CD154, important for T-cell function.
Conclusions:  Taken together, our findings indicate that HDAC inhibitors have an
immunomodulatory potential that may contribute to the potency and specificity of these
antineoplastic compounds and might be useful in the treatment of autoimmune disorders.
Background
Localized changes in chromatin structure are a key event
in the transcriptional regulation of genes [1]. Nucleo-
somes, the basic units of chromatin, consist of an octamer
of core histones (H2A, H2B, H3, and H4) wrapping 1.8
turns of DNA, and form a compact and hierarchical
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structure. Histone tails are subject to multiple posttransla-
tional modifications such as acetylation, phosphoryla-
tion, ubiquitination, methylation, and poly-ADP-
ribosylation, which play a role in transcriptional regula-
tion [2–4].
Reversible acetylation of the ε-amino group of lysine in
the histone tails by histone acetylases (HATs)/histone
deacetylases (HDACs) is one of the best-studied post-
translational modifications of histones, correlating with
transcriptional activation/repression. Thus, hyper-
acetylated histones are generally associated with transcrip-
tional permissiveness whereas hypoacetylated histones
mediate gene repression. HDACs were found to be associ-
ated with co-repressors [5–8] and as a consequence most
studies to date have focused on their role in transcrip-
tional repression. However, inhibitors of HDAC activity
(HDACIs) that increase histone acetylation by preventing
deacetylation, induce up- as well as down-regulation of a
small subset of genes [9–11], suggesting that chromatin
structure modulation by HDACs is a gene-specific event
with a variable transcriptional outcome, and that only a
few genes (approximately 2%) are regulated primarily
through HDAC-dependent mechanisms. Known com-
pounds that inhibit HDAC activity include sodium
butyrate, phenylbutyrate, trichostatin A (TSA), suberoy-
lanilide hydroxamic acid (SAHA), trapoxin (TPX), MS-
27–275, apicidin, oxamflatin, and FR901228 (for an over-
view see [12]). These agents are known to cause a variety
of effects in cell cultures including cell growth inhibition,
cell differentiation and apoptotic cell death, and to inhibit
the growth of cancer cells in animal models [13–18]. Fur-
thermore, therapeutic applications of HDACIs have
shown great promise in clinical studies. Some HDACIs
have also been shown to alter expression of genes
involved in immune processes, such as cytokines (IL-2
[19], IL-8 [20], IFNγ and IL-10 [21]), and costimulatory/
adhesion molecules (CD154 [21], MHC class II [22], and
CD86 [23]). T cells are activated physiologically by trig-
gering of the T-cell receptor-CD3 complex. There is evi-
dence that the induction of cytokine synthesis and
proliferation by T cell receptor (TCR)-mediated activation
requires costimulatory signals that can be provided by
additional cell surface molecules. Utilizing primary CD4+
T cells, we assessed the physiological effects of TSA on
lymphocytes. We demonstrate that various cellular func-
tions, such as proliferation and cytokine production, were
inhibited when T cells were exposed to TSA. Moreover,
expression of a subset of genes involved in T cell
responses, including a variety of costimulatory/adhesion
molecules, was reduced in cells treated with TSA. Thus,
histone deacetylase inhibitors possess not only anti-can-
cer activity but can also function as immunomodulators.
Methods
Cell cultures, mice and reagents
All cells were cultured in RPMI-1460 medium (BioWhit-
taker, Walkersville, MD) supplemented with 2 mM L-
glutamine, 0.01 M HEPES, 1 mM NaHCO3, 1 mM sodium
pyruvate, 10% fetal bovine serum (FBS), 0.1 mg/ml gen-
tamicin sulfate, and 50 µM β-mercaptoethanol (Sigma-
Aldrich). CD4+ T cells were isolated from erythrocyte-
depleted spleen cell preparations from C57BL/6 mice by
positive selection using magnetic microbeads coated with
anti-CD4 mAb according to manufacturer's instructions
(Miltenyi Biotec, Sunnyvale, CA). Naive CD4+ CD62L+
CD44low T cells were prepared using a negative selection
kit according to manufacturer's instructions (Mouse Naive
T Cell CD4+/CD62L+/CD44low Column Kit; R&D Systems
Inc., Minneapolis, USA). For cultures containing TSA,
concentrated solutions (10 × concentration) were freshly
prepared in RPMI from frozen stocks (10 mM TSA in
DMSO), whenever required, and diluted into cell suspen-
sions to the desired concentrations. Female C57BL/6 mice
were purchased from Bomholtgaard Ltd. (Ry, Denmark).
All animals were allowed to acclimatize to the local envi-
ronment for at least 1 week before being used for any
experiment, by which time they were 8–10 weeks old.
Animals were housed under pathogen-free conditions and
all experiments were conducted in accordance with
national guidelines.
Isolation of RNA and semi-quantitative reverse 
transcriptase PCR
Total RNA from TSA-treated and untreated cells was iso-
lated using the Absolutely RNA™ RT-PCR kit from Strata-
gene. Cell populations cultured for 20 h were enriched for
live cells by centrifugation in Ficoll Paque before RNA iso-
lation. One hundred ng total RNA was analysed by semi-
quantitative RT-PCR using SUPERSCRIPT™ One-step RT-
PCR kit (Invitrogen, Carlsbad, CA) and the following
primers:
CD28 forward and reverse primers 
5'-GCTGTTCTTGGCTCTCAACT-3' and 
5'-TCGAGCGAAACTGGGGCTGA-3', respectively;
MetAP2 forward and reverse primers 
5'-TTCGGTACCCTTGCCTTCTG-3' and 
5'-TTAATAGTCATCTCCTCTGC-3', respectively; p27 for-
ward and reverse primers 
5'-ATGTCAAACGTGCGAGTGTC-3' and 
5'-TTACGTTTGACGTCTTCTGAG-3', respectively; GATA-2
forward and reverse primers 
5'-ACTATGGCAGCAGTCTCTTCCATC-3' and 
5'-AAGGTGGTGGTTGTCGTCTGAC-3', respectively; p21
forward and reverse primers 
5'-GATGTCCGTCAGAACCCATG-3' and 
5'-TTAGGGCTTCCTCTTGGAGA-3', respectively; NUR77
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5'-GTTGATGTTCCCGCCTTTGCC-3' and 
5'-TCAGAAAGACAATGTGTCCAT-3', respectively; LAT
forward and reverse primers 
5'-AGGATGAAGACGACTATCCC-3' and 
5-TTCACACGACTCCACAGAGA-3', respectively; p16 for-
ward and reverse primers 
5'-GATGGGCAACGTTCACGTAG-3' and 
5-CGGAACACAAAGAGCACCCA-3', respectively; IL-2
forward and reverse primers 
5'-GAATGGAATTAATAATTACAAGAATCCC-3' and 
5'-TGTTTCAGATCCCTTTAGTTCCAG-3', respectively.
Primers specific for 18S RNA-QuantumRNA™ Classic 18S
Internal Standard- were purchased from Ambion
(Ambion, Austin, TX).
Microarray analysis
Gene expression analysis was performed using Clontech's
Atlas™ expression arrays (mouse 1.2 and 1.2 II) in accord-
ance with the manufacturer's instructions. Briefly, in two
independent preparations 50 µg of total RNA were iso-
lated from CD4+ T cells grown under treated and non-
treated conditions, using Atlas™ Pure Total RNA labelling
system (Clontech) and polyA+ RNA purified and retro-
transcribed in the presence of [α-32P]dATP. Labelled
cDNAs were hybridized overnight to paired membranes
(2 membranes per assay) under stringent conditions.
Membranes were extensively washed and subsequently
analysed on a Fuji BAS 2500 Image Analysis System (FUJI-
FILM Medical Systems, Stamford, CT, USA). A complete
list of the genes present in the used arrays and a full
instructions manual can be found at http://www.clon
tech.com/atlas/genelists/index.shtml.
T cell proliferation and cytokine quantification
Latex beads (Interfacial Dynamics Corp., Portland, OR)
were coated with antibodies specific for CD3, CD3/CD28,
or hamster IgG (isotype control) as described [24]. For
determination of IL-2 production, 1 × 105 CD4+ cells were
cultured in round-bottom 96-well plates (Nunc, Roskilde,
Denmark) under the conditions of the specific assay. Sub-
sequently, the supernatant was removed for analysis and
the cells were washed, fixed, and permeabilized for intra-
cellular staining and analysis by FACS using Cytofix/
Cytoperm Plus kit as per manufacturer's instructions
(Pharmingen). Levels of IL-2 in the supernatant were
quantified by a sandwich enzyme-linked immunosorbent
assay using specific antibody pairs from Pharmingen
(JES6-1A12 and JES6-5H4) and recombinant murine
interleukin-2 (rmIL-2; Roche Molecular Biochemicals) as
standard.
Monoclonal antibodies, 5-carboxyfluorescein diacetate 
succinimidyl ester staining, and flow cytometry analysis
Flow cytometric analysis of cell surface molecules was per-
formed by incubating 1 × 105 cells with isotype-matched
control antibody or a relevant antibody at 4°C for 30 min-
utes. Phycoerythrin (PE) and fluorescein isothiocyanate
(FITC) conjugated as well as non-conjugated antibodies
were purchased from Pharmingen. After washing twice
with phosphate-buffered saline (PBS) supplemented with
2% FBS, the cells were analysed on a FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA) equipped
with CellQuest software. Samples incubated with isotype-
matched control antibodies were used as reference for the
placement of logic quadrants and gates.
5-carboxyfluorescein diacetate succinimidyl ester (CFSE)-
staining was performed according to manufacturer's
instructions (Molecular Probes, OR).
Determination of ROS generation
ROS production upon treatment with TSA was assessed by
oxidation of the dyes 2',7'-dichlorodihydrofluorescein
diacetate (DCFDA; Molecular Probes) and dihydroethid-
ium (DHE; Molecular Probes, OR) to the fluorescent
products 2',7'-dichlorofluorescein (DCF) and ethidium
(Eth), respectively, as measured by flow cytometry. DHE
and DCFDA were added to cultures at a final concentra-
tion of 2 µM 15 min before harvest. The incubation was
terminated by 10-fold dilution with ice-cold PBS buffer
before the cells were washed and submitted to FACS
analysis.
Apoptosis and cell cycle analysis
For detection of apoptosis, approximately 104 cells were
collected, stained with Annexin V: FITC Apoptosis Detec-
tion Kit I according to manufacturer's instructions
(Pharmingen) and analysed by FACS. For cell cycle analy-
sis, 2–3 × 104 cells were collected in DNA staining solu-
tion (0.1% sodium citrate, 0.3% NP-40, 0.02 mg RNase A
per ml, 0.05 mg of propidium iodide per ml) and incu-
bated for 30 min. DNA content was subsequently ana-
lysed by FACS. In both cases FACS analysis was performed
on a FACSCalibur flow cytometer equipped with Cel-
lQuest software.
Western blot analysis
Crude cell extracts for Western blotting (nuclear+cytoplas-
mic) were prepared from approximately 1 × 106 cells using
the NE-PER® Nuclear and Cytoplasmic Extraction Reagen
Kit (Pierce, Rockford, IL), according to the manufacturer's
protocol. Extracts were resolved on NuPAGE 4–12% gels
(Invitrogen, Carlsbad, CA), blotted onto PVDF mem-
branes (Invitrolon, Invitrogen) and detected using Super-
signal WestPico detection reagents according to
manufacturer's instructions (Pierce, IL).BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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Results
Trichostatin A inhibits T-cell proliferation and induces cell 
death
The ability of HDACIs to cause cell growth arrest, differen-
tiation and apoptotic cell death of cultured tumor cells is
well established [10,13–17]. However, with a few notable
exceptions the majority of the studies done on the effects
of HDACIs were performed using transformed or other-
wise immortalized cell lines. Since cancer cells have
altered levels of histone acetylation and DNA methyla-
tion, the effects caused by HDACIs in these cells probably
do not completely reflect the situation in normal cells. In
fact, a recent report showed that normal cells are less sen-
sitive to HDAC inhibition than transformed counterparts
[25]. To address the question of the differential sensitivity
to HDACIs of tumor cells as compared to normal cells,
and to gain some insight into the pharmacological mech-
anism of action of these compounds in non-transformed
cells, particularly in lymphocytes, we set out to character-
ize the effects of HDACIs on normal primary murine
CD4+ T lymphocytes.
CD4+ T-cells were purified from C57BL/6 spleen cells and
treated for 24 hours with increasing concentrations of a
specific HDAC inhibitor, Trichostatin A (TSA). As shown
in Figure 1A, there was a dose-dependent reduction in cell
viability. Exposure to less than 5 nmol/L TSA reduced the
viability of CD4+ T-cells by approximately 50%. These
findings indicate that primary CD4+ T-cells are sensitive to
HDAC inhibitors at effective concentrations similar to
those reported for a variety of transformed cells
[12,17,23,26].
To ascertain if the decrease in cell viability is due to induc-
tion of apoptosis, we performed Annexin V staining of
treated cells. FACS analysis of TSA-treated CD4+ T cells
showed staining with Annexin V, with the number of
Annexin V positive cells increasing in a time and dose-
dependent manner (Figure 1B) arguing for TSA-induced
apoptotic cell death of lymphocytes. Next we investigated
the cell-cycle pattern of TSA-treated T cells, as TSA is
known to inhibit cell proliferation and to cause cell cycle
arrest in human cancer cells. Red blood cell-depleted
splenocytes from C57BL/6 were stimulated with either IL-
2 or soluble anti-CD3 mAb for 24 h, after which CD4+ T
cells were purified and exposed to TSA for 20 h. Cells were
subsequently analyzed for their cell cycle distribution
(Figure 1C). As can be seen from the DNA content profile,
cells exposed to TSA that had not yet undergone apoptosis
(8% and 5.3 % for IL-2 and anti-CD3 stimulated cells,
respectively) accumulated in the G0/G1 phase of the cell
cycle (corresponding to region M1). This cell cycle arrest is
reversible as shown in Figure 1D. T cell proliferation was
measured as described previously, by labeling cells with
CFSE and evaluating cell divisions by the decrease in CFSE
fluorescence intensity [27]. On day 3 after removal of TSA
from the medium, cells either remain undivided or have
undergone one cell division. On day 8 the remaining
CFSE+ cells have most proliferating cells in division peak
5 and 6, indicating that once TSA is removed, those cells
that have not become apoptotic are able to proliferate for
at least 6 cell divisions. We concluded that TSA induces
apoptotic cell death of CD4+ T cells and reversible cell
growth arrest.
TSA leads to increased generation of reactive oxygen 
species and activates a caspase-independent cell-death 
pathway
The induction of apoptosis of tumor cells by histone
deacetylase inhibitors has been show to occur in several
cases through a caspase-dependent mechanism including
the conversion of the proenzyme form of a caspase to the
catalytically active effector protease and concomitant up-
or down-regulation of apoptosis regulatory proteins such
as Daxx, bcl-xL, Bcl-2, Bid or Bad [18,28–31]. Various
authors have argued that inhibition of HDAC activity
leads to chromatin relaxation and enhanced gene expres-
sion of, among others, specific cell-death regulating genes.
However, this view has been questioned by several recent
studies that suggest that histone hyperacetylation alone
cannot account for all the cellular effects of deacetylase
inhibitors [32–34] suggesting an additional mecha-
nism(s) of action for HDACIs.
To determine whether new transcription and protein syn-
thesis are required for induction of apoptosis by TSA, we
used the transcriptional inhibitor actinomycin D (act-D)
and the protein synthesis inhibitor cycloheximide (CHX).
Treatment of CD4+ T-cells with act-D and CHX effectively
protected the cells from TSA-induced cell death with the
graphic showing almost complete inhibition of TSA-
induced apoptosis by CHX and act-D (Figure 2A), indicat-
ing that de novo mRNA and protein synthesis is required
for TSA-induced apoptosis of CD4+ T-cells.
Trichostatin A has been shown to induce activity of effec-
tor caspases such as caspase 3 in Jurkat lymphoid, LIM
1215 colorectal cancer cell lines, and hepatoma cells
HepG2, MH1C1, Hepa1-6 and Hep1B [35,36]. Because
TSA induced caspase-3 activity by more than 10-fold in
Jurkat cells (a lymphoid cell line) we asked if this was also
the case in primary lymphocytes. We saw no significant
alteration in the levels of procaspase-3 or the active p20
and p11 caspase 3 fragments in CD4+ T-cells incubated for
20 h in the presence of medium containing growing con-
centrations of TSA (Figure 2B, upper panel). We also
examined expression of an inducer caspase, caspase 10.
We could detect an increase (5–6 fold) in the expression
of procaspase-10 in TSA treated cells compared to control
cultures (-TSA). Nevertheless, the levels of the active p20BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
Page 5 of 18
(page number not for citation purposes)
TSA induces apoptosis and cell cycle arrest in CD4+ T-cells Figure 1
TSA induces apoptosis and cell cycle arrest in CD4+ T-cells. (A) CD4+ T-cells were treated for 24 hours with increas-
ing concentrations of TSA (■ ). Cell death was determined by flow cytometric analysis of DNA content by PI staining of nuclei. 
Error bars show SD. (B) CD4+ T-cells were treated for 8 or 20 hours with various concentrations of TSA or DMSO alone as 
a negative control (-TSA). Cells were subsequently stained with Annexin V and PI. Inset in the bottom right quadrant of each 
plot are the percentage of cells that gated to the various quadrants (UL – upper left; UR – upper right; LL – lower left; and LR 
– lower right). The numbers for LR correspond to cells in early apoptosis (Annexin V positive and PI negative). (C) Effect of 
TSA on cell cycle progression of T cells. CD4+ T-cells were incubated for 24 h in the presence of medium containing IL-2 (10 
U/ml), or anti-CD3 coupled beads (2:1 beads to cells ratio) after which either TSA (final concentration of 10 nM) or DMSO 
alone was added. After 20 hours the cells were analysed for cell cycle distribution by flow cytometry. Data are plotted as DNA 
content (propidium iodide fluorescence) vs relative live cell number (cells gated to R1). The total percentages of cells in the G0/
G1 (region M1), S (region M2), and G2/M (region M3) phases of the cell cycle are shown. (D) Live TSA-treated cells (20 h with 
10 nM TSA) were isolated by centrifugation in Ficoll Paque, washed extensively, labelled with CFSE and incubated in the pres-
ence of anti-CD3 coated beads (2:1 bead to cell ratio). Proliferation status of T cells was evaluated after 24 h (gray shaded his-
togram), 72 h (black open histogram), and 8 days (open gray histogram). Arrows indicate CFSE division peaks. For simplicity 
dead cells were excluded from the analysis. The data are representative of three independent experiments.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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TSA generates ROS and activates the caspase-dependent cell death pathway Figure 2
TSA generates ROS and activates the caspase-dependent cell death pathway. (A) Effect of cycloheximide and 
actinomycin-D on TSA-induced apoptosis. CD4+ T-cells were pre-treated with either CHX or act-D for 1 h after which TSA 
was added to the culture medium at a final concentration of 100 nM. After 20 h, levels of apoptosis were assessed by PI stain-
ing. (B) Western blots showing the effect of TSA on levels of caspase-3 and -10. CD4+ T-cells were cultured for 20 h in the 
presence of medium containing growing concentrations of TSA or DMSO alone (-TSA). After 20 hours the cells were har-
vested and cell extracts prepared as described in the Materials and Methods section. Western blots were prepared using one 
of the following antibodies: caspase-3 (H-277), or caspase-10 p20 (H-131) from Santa Cruz Biotechnology, Inc. (USA). Revers-
ible staining of blots with Ponceau S was used as loading and blotting control. A typical blot is shown. (C) Effect of TSA on cell 
death receptor expression. Spleen cells from C57BL/6 mice were cultured for 48 h in the presence of soluble anti-CD3 anti-
body (0.5 µg/ml), whereafter CD4+ T-cells were isolated by magnetic cell separation as described (materials and methods sec-
tion). Cells were subsequently stimulated with immobilized anti-CD3 mAb or cultured in the presence of IL-2 (10 U/ml), 
harvested after 20 hours in the presence of various concentrations of TSA, and the levels of CD95 and CD95L analysed by 
flow cytometry. Inset in the upper right quadrant of each plot are the percentage of cells that gated to the various quadrants 
(UL – upper left; UR – upper right; LL – lower left; and LR – lower right). Logic quadrants were placed such that the cells in a 
non-stimulated sample gate to the LL quadrant. Only live cells are included in the analysis. (D) TSA induces ROS generation. 
CD4+ T-cells were incubated for 24 h in the presence of medium containing IL-2 (10 U/ml), or anti-CD3 coupled beads (2:1 
beads to cells ratio) after which either TSA (final concentration of 10 nM; bold black open histogram) or DMSO alone (black 
open histogram) was added. After 20 hours the cells were analysed for DHE and DCFDA fluorescence. (E) TSA-induced T-cell 
apoptosis can be inhibited by free radical scavengers and mitochondrial inhibitors. CD4+ T-cells were incubated for 24 h in the 
presence of medium containing IL-2 (10 U/ml), subsequently treated with SOD (2000 U/ml in the presence of 100 nM of digi-
tonin), catalase (3000 U/ml), antimycin A (50 µM), or valinomycin (50 µM) for 1 h, after which TSA was added to the culture 
medium at growing concentrations. After 20 h, cells were harvested, and cell survival was determined by PI staining of nuclei. 
Shown are the mean percentage of survival; bars, SD. All data are representative of two independent experiments. A typical 
blot is shown.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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fragment of caspase-10 remained largely unaltered (Figure
2B, lower panel) suggesting that TSA-mediated T-cell
death is a caspase independent event.
Exposure to M-carboxycinnamic acid bishydroxamide
(CBHA), a recently developed hybrid polar compound
and a potent inhibitor of HDAC activity, leads to apopto-
sis in human neuroblastoma cell lines, with a concomi-
tant induction of expression of both CD95 (APO-1/Fas)
and CD95 ligand (FasL) [13]. Signals from members of
the tumor necrosis factor receptor family, such as CD95/
Fas, can result in apoptotic cell death. To ascertain if TSA
up-regulates CD95/Fas and/or CD95L/FasL in T-cells thus
leading to increased CD95/Fas-induced apoptosis, we
examined the cell surface expression of these molecules in
CD4+ T-cells, after exposure to growing concentrations of
TSA for 20 hours (Figure 2C). Expression of CD95/Fas was
decreased by TSA treatment both in cells stimulated with
anti-CD3 and with IL-2. Thus, the percentage of IL-2-stim-
ulated live cells showing high levels of CD95/Fas
decreased from 3.72% in non-treated cells (-TSA) to
0.88% in cells treated with 100 nM TSA. In cells stimu-
lated with anti-CD3 this decrease is even more noticeable,
with the number of live cells displaying high levels of
CD95/Fas decreasing from 22.54% in non-treated cells (-
TSA) to 1.02% in TSA-treated cells (+TSA 100 nM). Con-
versely, expression of CD95L/FasL was increased by TSA
treatment both in cells stimulated with anti-CD3 and with
IL-2, with the percentage of IL-2-stimulated live cells that
showed high levels of CD95L/FasL increasing from 0.72%
in non-treated cells (-TSA) to 4.44% in cells treated with
100 nM TSA. In cells stimulated with anti-CD3 the
number of live cells displaying high levels of CD95L/FasL
increased from 1.78% in non-treated cells (-TSA) to
3.98% in TSA-treated cells (+TSA 100 nM). Interestingly,
IL-2 stimulated cells displaying low levels of CD95L/FasL
are depleted from the cell population by TSA treatment.
Taken together, these results suggest that TSA-induced
apoptotic cell death in T-cells cannot occur exclusively via
activation of the Fas/FasL pathway, but that the observed
up-regulation of CD95L expression might contribute to
the apoptotic effect of TSA.
One possible way the intrinsic cell death pathway can be
activated is through cytochrome c release from mitochon-
dria. Hence, mitochondria might in some way be
involved in TSA-induced cell death. We decided therefore
to investigate the role of mitochondria in CD4+ T-cell
apoptosis by TSA. We tested the production of ROS by
staining with the dyes DHE and DCFDA, which are oxi-
dized to fluorescent products in the presence of superox-
ide and peroxides, respectively [37]. TSA-treated CD4+ T-
cells showed increased production of peroxides and
superoxide (Figure 2D). Cells grown in the presence of
TSA had a shift in the mean fluorescent value for DCFDA
as well as DHE, showing that TSA induces production of
peroxides and superoxide. As shown in Figure 2E, pre-
treatment of CD4+ T-cells with several radical scavengers
and mitochondrial respiration inhibitors significantly
reduced TSA-induced apoptosis. Thus, antimycin A (a ubi-
quinol-cytochrome c reductase inhibitor), and valinomy-
cin (a K+  ionophore, which dissipates the ∆ψm  and
interferes with electron transport) almost completely
inhibited the apoptotic effect of TSA, whereas superoxide
dismutase (SOD) and catalase, two free radical scaven-
gers, partially inhibited the apoptotic effect of TSA (Figure
2E). These results show that the apoptotic effect of TSA in
T-cells involves mitochondria and suggest a crucial role
for mitochondrial respiratory chain (MRC) in TSA-
induced apoptosis.
TSA represses interleukin-2 gene expression in T-cells
Histone deacetylase inhibitors have been reported to sup-
press expression of cytokines in lymphocytes [19–21,38].
We set out to determine if TSA could affect IL-2 produc-
tion in normal primary T-cells stimulated in vitro under
defined conditions. We subjected cells to a strong activat-
ing signal that induces them to produce high levels of IL-
2 [24,39]. Thus, CD4+ T-cells were stimulated with immo-
bilized antibodies, either anti-CD3, or anti-CD28, or a
combination of both (bead to cell ratio of 2:1). As
expected, IL-2 was secreted by cells stimulated with
immobilized anti-CD3 (~16 pg/ml IL-2) and anti-
CD3+anti-CD28 (~37 pg/ml IL-2) but not with anti-
CD28 alone or isotype control (trinitrophenol-specific
hamster IgG) (Figure 3A). Cells treated with TSA (10 or
100 nM) showed a decrease in IL-2 levels of approxi-
mately 50–70%. Semi-quantitative RT-PCR analysis of
CD4+ T-cells cultured in the presence of 100 nM TSA for 4,
8, and 20 hours, showed that the decrease in IL-2 produc-
tion occurs at the transcriptional level, with levels of IL-2
mRNA declining by >50–60% already after 4 hours of
exposure to 100 nM TSA (Figure 3B). After 8 hours, the
levels of IL-2 mRNA are 5–6 fold lower in TSA-treated cells
as compared to non-treated cells. And after cells have been
cultured for 20 h in the presence of TSA, IL-2 expression is
down to nearly undetectable levels.
To determine if the decrease we detected in IL-2 expres-
sion was due to a general decrease in expression or abro-
gation of expression in part of the cell population in TSA-
treated samples, we performed single-cell analysis of
intracellular levels of IL-2 by flow cytometry. As shown in
Figure 3C, approximately 19% of live cells in the cell pop-
ulation produce high levels of IL-2 when stimulated with
immobilized anti-CD3. This amount of IL-2 producing
cells drops to 9.8% and 4.7%, when cells are exposed to
50 and 100 nM TSA, respectively. These data show that
TSA specifically represses IL-2 expression in affected CD4+
T-cells.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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TSA represses IL-2 gene expression Figure 3
TSA represses IL-2 gene expression. Spleen cells from C57BL/6 mice were cultured for 48 h in the presence of soluble 
anti-CD3 antibody (0.5 µg/ml), whereafter CD4+ T-cells were isolated by magnetic cell separation as described in the materials 
and methods section. Cells were subsequently stimulated with the indicated immobilized antibodies and in the presence of the 
indicated inhibitors. (A) Inhibitors or DMSO alone (vehicle) were added to the medium – TSA (final concentration of 10 nM 
or 100 nM). After 8 hours the supernatant was harvested and IL-2 levels quantified by ELISA. (B) Purified CD4+ T-cells stimu-
lated with immobilized anti-CD3 mAb were harvested after 4, 8, or 20 hours in the presence of 100 nM TSA, and levels of IL-
2 mRNA quantified by relative RT-PCR as described (materials and methods section). Primers for 18S rRNA were used as 
control. (C) CD4+ T-cells stimulated with immobilized anti-CD3 mAb and cultured in growing concentrations of TSA were 
harvested after 8 hours and intracellular levels of IL-2 analysed by flow cytometry. Dead cells are excluded from the analysis. 
The data are representative of three independent experiments.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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Inhibition of cytokine expression is not responsible for 
HDACIs apoptotic effect
Chromatin-mediated repressive effects on gene transcrip-
tion are usually ascribed to DNA methylation or histone
deacetylation and several studies have shown that it is
possible to pharmacologically revert some of these effects
(40,41). Histone deacetylase inhibitors on the other hand
are presumed to function by increasing histone acetyla-
tion and derepressing target genes. Nonetheless, TSA
specifically affects IL-2 production in human leukemic
Jurkat T cells, and decreases IL-2-mediated gene expres-
sion in IL-2-dependent cells [19,26,42]. Interestingly,
HDAC inhibitors readily induce apoptosis in IL-2-
dependent cells and transfectants expressing the IL-2
receptor c chain, but they show a far less apoptotic poten-
tial in cytokine-independent cells even though these
inhibitors increase acetylation levels of histones to a sim-
ilar degree in both cells [26]. Given the biological role IL-
2-mediated gene expression plays in cell survival, these
data suggest that its repression may contribute to the
apoptotic process induced by HDAC inhibitors. To test
this possibility we looked at cell survival of CD4+ T-cells
exposed to 100 nM TSA and cultured in the presence of
growing concentrations of rmIL-2 (Figure 4A). Addition
of rmIL-2 increased the survival potential of CD4+ T-cells,
peaking at 10 U/ml after which a decline in cell survival
ensues. This pattern is identical for TSA-treated or non-
treated cells, showing that IL-2 cannot rescue the apopto-
sis induction by TSA in CD4+ T-cells. Nor can addition of
several other survival cytokines, such as IL-4, IL-1α, and
IL-12 (Figure 4B). Strong activating stimuli such as co-
immobilized antibodies against CD3 and CD28 (Figure
4B), phorbol esters (phorbol-12-myristate-13-acetate) in
combination with ionophores (ionomycin), or lectins
(concanavalin A), were also unable to rescue cells from
TSA-induced apoptosis (data not shown). These results
indicate that external stimuli, that normally induce prolif-
erative or survival signalling pathways, cannot negate the
apoptotic effect of TSA on CD4+ T-cells.
TSA affects the NFκB signalling pathway
The transcription factor NFκB is a crucial regulator of
immune and inflammatory responses, controlling the
expression of a plethora of genes including cytokine,
cytokine receptor, chemokine, cell adhesion molecule,
and other cell surface receptor genes [42,43]. Members of
the NFκB/Rel family of transcription factors, such as
NFκB1 (p105/p50), NFκB2 (p100/p52), RelA/p65, RelB,
and c-Rel, are predominantly located in the cytoplasm of
unstimulated cells [44]. Upon a variety of stimuli the
inhibitory proteins known as IκB proteins, which bind
NFκB proteins keeping them in a functionally inactive
state, are specifically phosphorylated. This modification
leads to ubiquitination and degradation of IκB by the 26S
proteosome and results in nuclear translocation of NFκB
and the activation of a variety of target genes [45]. One
such target is IL-2, suggesting that TSA might abrogate
expression of this cytokine by inhibiting NFκB-mediated
regulation. We investigated if decreased levels of nuclear
NFκB mediate the effect TSA has on IL-2 expression. West-
ern blot analysis of nuclear protein extracts of CD4+ T-cells
exposed to growing concentrations of TSA shows a dose-
dependent drop in the level of nuclear NFκB protein after
Addition of exogenous cytokines does not rescue TSA- treated cells Figure 4
Addition of exogenous cytokines does not rescue 
TSA-treated cells. (A) Effect of IL-2 on cell survival. CD4+ 
T-cells were isolated by magnetic cell separation from 
C57BL/6 mouse splenocytes and cultured in medium con-
taining 100 nM TSA (+TSA) or DMSO alone (-TSA) for 20 
hours in the presence of growing concentrations of rmIL-2 
(0–200 U/ml). Cell survival of TSA-treated cells is plotted in 
the right coordinates axis whereas that of non-treated cells is 
plotted in the left axis. (B) Effect of exogenous cytokine 
addition on cell survival. CD4+ T-cells were cultured in 
medium containing TSA at growing concentrations (+TSA) 
or DMSO alone (-TSA) and in the presence of various 
cytokines or stimuli (legend inset in graphic). PI staining of 
nuclei determined cell survival after 20 hours. Shown is the 
mean percentage of survival; bars represent SD. All data are 
representative of three independent experiments.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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stimulation with PMA/ionomycin (Figure 5A). Thus, cells
treated with 100 nM TSA had 3–4 fold lower levels of
nuclear NFκB protein as compared to control untreated
cells (-TSA), suggesting that TSA inhibits nuclear
translocation of NFκB. A recent report has shown that
LPS-induced translocation of NFκB p65 from the cyto-
plasm to the nucleus in peripheral blood mononuclear
cells (PBMCs) is inhibited by butyrate. This effect is appar-
ently mediated by inhibition of IκB degradation [46].
Consequently, we investigated if the TSA-mediated
decrease in nuclear NFκB was due to inhibition of IκBα
degradation. Western blot analysis of cytoplasmic CD4+ T-
cell protein extracts showed a drastic drop in IκBα levels
just 15 min after stimulation with PMA/ionomycin
declining to even lower levels after 30 min, and maintain-
ing a low level of expression thereafter (Figure 5A). This
pattern was unaltered by TSA (Figure 5B). We concluded
that TSA does not inhibit PMA/ionomycin-induced degra-
dation of IκBα, and that the decrease in the levels of
nuclear NFκB observed in TSA-treated cells occurs by
some mechanism(s) other than inhibition of IκBα
degradation.
TSA modulates expression of many cell surface molecules
Recent studies have demonstrated that HDACIs can mod-
ulate expression of several costimulatory/adhesion mole-
cules not only in cell lines but also in clinical samples
[21,23]. Since adequate expression of costimulatory/
adhesion molecules is essential for proper T-cell
responses, be it cell survival, activation or proliferation
[47–50], we decided to analyze the expression levels of
various cytokine receptors, cell adhesion molecules, and
cell surface receptors in a cell population treated with TSA.
Splenocytes from C57BL/6 mice were stimulated with sol-
uble anti-CD3 antibody (0.5 µg/ml) or IL-2 (10 U/ml)
and exposed to 100 nM TSA. Samples were taken after 4
and 20 hours, and expression of cell surface markers
examined by flow cytometry (Figure 6A). CD4+ T-cells
stimulated with IL-2 and exposed to TSA for 4 hours,
exhibited lower levels of expression of CD11c, CD69,
CD28, CD40, and CD40L, and higher levels of expression
of IL2Rβ with all others remaining constant. After 20
hours of exposure IL2Rβ, ICAM-1, CD8a, CD11c,
CD45RB, CD69, CD28, CD40L, CD80, CD86 and CD95
were downregulated to various extents, but none of the
NFκB signalling is affected by TSA Figure 5
NFκB signalling is affected by TSA. (A) Effect of TSA on levels of nuclear NFκB. CD4+ T-cells were cultured with various 
concentrations of TSA (+TSA) or DMSO alone (-TSA) for 8 hours, whilst concomitantly stimulated with PMA+ionomycin (50 
ng/ml and 1 µg/ml, respectively), or not stimulated (-PMA/ionomycin). Nuclear extracts were analysed for the presence of 
NFkB by western blot analysis using an antibody raised against NFκB p65 (C-20) (Santa Cruz Biotechnology, Inc. USA). (B) 
Effect of TSA on IκBα expression. CD4+ T-cells were pretreated with either 100 nM TSA (+TSA) or DMSO alone (-TSA) for 4 
hours, whereafter phorbol-12-myristate-13-acetate (PMA; 50 ng/ml) and ionomycin (1 µg/ml), or vehicle (-PMA/ionomycin) 
was added to the medium and the cells were cultured for various periods of time. Cell lysates were analysed for IκBα expres-
sion by Western blot analysis using an anti-IκBα antibody from Cell Signaling Technology (CST, Beverly, MA). Reversible stain-
ing of blots with Ponceau S was used as loading and blotting control.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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examined molecules was upregulated. In non-CD4 cells
stimulated with IL-2 and exposed to TSA for 4 hours, the
pattern of effects was very similar. Thus, expression of
CD11c, CD69, CD28, CD40, and CD40L was downregu-
lated, whereas expression of IL2Rβ was increased. After 20
hours of exposure, IL2Rα, IL2Rβ, LFA-1, ICAM-1, CD8a,
CD11b, CD11c, CD45RB, CD69, CD28, CD40, CD40L,
CD48, CD86, and CD95 were downregulated to various
extents, but of the examined molecules only CD80 was
upregulated. Stimulation of PBMCs with anti-CD3 led to
profound alterations in the profile of TSA-mediated cell
surface molecule expression. CD4+ T-cells exposed to TSA
for 4 hours, exhibited higher levels of expression of
CD11c and ICAM-1 with all others remaining constant.
After 20 hours of exposure, IL2Rα, IL2Rβ, LFA-1,
CD45RB, CD28, CD40, CD40L, and CD48 were down-
regulated, whereas ICAM-1 and CD69 were upregulated.
In non-CD4 cells treated with TSA for 4 hours levels of
expression of CD11c were increased. After 20 hours of
exposure, IL2Rα, IL2Rβ, LFA-1, ICAM-1, CD8a, CD11c,
CD28, CD40L, and CD95 were downregulated, and
CD11b, CD40, and CD86 were upregulated. These results
demonstrate that HDAC inhibitors may modulate T-cell
function in part through changes in the expression of cell
surface proteins.
The differences in expression of cell surface molecules,
such as CD95/Fas, in PBMCs in the two cell subpopula-
tions we examined (CD4+ T-cells versus non-CD4 cells)
suggested to us that the various cell types might be
affected to different extents by TSA. To clarify this point,
we cultured PBMCs in the presence of either soluble anti-
CD3 antibody (+CD3) or IL-2 (+IL-2) and treated with
TSA (+TSA) or DMSO for 20 hours. Subsequently, cells
were analyzed by flow cytometry to determine cell viabil-
ity and the ratio of CD4+ T-cells versus non-CD4 cells.
Plotting of the percentage of total viable cells in the pop-
ulation shows that TSA induces apoptosis in PBMCs to a
similar extent in anti-CD3 or IL-2 stimulated cells (Figure
6B; leftmost bar set). Correspondingly, plotting the per-
centage of live CD4+ T-cells in the total cell population
reveals that TSA induces apoptosis in CD4+ T-cells to a
similar extent in anti-CD3 or IL-2 stimulated cells (Figure
6B, middle bar set). However, plotting the number of
CD4+ T-cells as a percentage of the viable cell population
shows an interesting effect of TSA. Whereas in the IL-2
stimulated control cell population roughly 22% of the
viable cells are CD4+ T-cells, in the TSA-treated cell popu-
lation almost 41% of the viable cells are CD4+ T-cells (Fig-
ure 6B; rightmost bar set). The opposite is true in anti-
CD3-stimulated cells, where the percentage of CD4+ T-
cells decreases from 38% in non-treated cells to 28% in
TSA-treated cells. We interpreted these data to reflect the
abrogation of IL-2 expression caused by TSA. Exogenously
added IL-2 keeps preferentially CD4+  T-cells alive, an
TSA modulates expression of cell surface molecules Figure 6
TSA modulates expression of cell surface molecules. 
(A) PBMCs from C57BL/6 mice were cultured in the pres-
ence of soluble anti-CD3 antibody (0.5 µg/ml) or IL-2 (10 U/
ml) and exposed to 100 nM TSA for 4 hours (open black his-
togram) and 20 hours (open blue histogram), or to DMSO 
alone for 4 hours (open red histogram) or 20 hours (open 
brown histogram). Cells were harvested, extensively washed, 
and flow cytometric analysis of cell surface molecules per-
formed as described in the materials and methods section. 
Dead cells are excluded from the analysis. (B) PBMCs from 
C57BL/6 mice were cultured in the presence of soluble anti-
CD3 antibody (0.5 µg/ml) or IL-2 (10 U/ml) and exposed to 
100 nM TSA or to DMSO alone for 20 hours. Cells were 
harvested, stained with a PE-conjugated anti-CD4 antibody 
and analysed by flow cytometry. PI staining of nuclei assessed 
cell viability. Shown are the mean percentage of survival; 
bars, SD. The data are representative of three independent 
experiments.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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effect that becomes very significant in the presence of TSA.
On the other hand, anti-CD3 alone induces cell death in
CD4+ T-cells, an effect that is exacerbated in the presence
of TSA given the lack of production of endogenous IL-2 by
activated CD4+ T-cells.
TSA regulates transcription of many genes in a negative as 
well as in a positive manner
To examine the differential patterns of gene expression
resulting from TSA treatment, we used high-density
expression arrays from Clontech (Atlas™ mouse 1.2 and
1.2 II). In order to minimize variations in gene expression
unrelated to the treatment with TSA, we decided to use a
more uniform T cell population, specifically, naïve CD4+
CD62L+ CD44low cells. Figure 7A shows a list of the genes
that were reproducibly affected after 4 hours of treatment
with 100 nM TSA. Out of the 2352 genes examined only
48 showed significant (>2-fold variation) and reproduci-
ble (less than 20% variation in two independent mRNA
preparations) changes in levels of expression in cells
treated with TSA. This corresponds to approximately 2%
of the examined genes showing that TSA acts rather selec-
tively on gene expression in CD4+ T cells.
To verify the changes in transcription detected by our
microarray analysis, we performed semi-quantitative RT-
PCR analysis on selected TSA responsive genes. We chose
a subset of genes revealed by our microarray analysis to be
HDAC-dependent (MetAP2, LAT, and HMG14) as well as
a subset of genes not identified in our analysis and shown
to have HDAC-dependent transcriptional regulation
(Nur77, CD28, GATA-2, p27Kip1, and p16/Ink4a/Arf). The
time-dependency in the TSA-mediated effects, which we
had observed in the expression of cell surface molecules
(Figure 6B), prompted us to perform the RT-PCR analysis
at various time points (1, 4, and 20 hours of treatment
with TSA). Various genes exhibited a heterogeneous
behavior with a time and stimulus dependency. Thus,
levels of p27Kip1 (a cyclin-dependent kinase inhibitor)
were drastically increased after 20 hours of treatment with
TSA in IL-2 stimulated cells but not in anti-CD3 stimu-
lated cells. Expression of Nur77 (an orphan member of
the nuclear hormone receptor superfamily) was upregu-
lated in IL-2 stimulated cells both after 4 and 20 hours,
but it was upregulated after 4 hours and downregulated
after 20 hours in anti-CD3 stimulated cells. Levels of
MetAP2 mRNA (methionine aminopeptidase 2) were
decreased already after 1 hour of exposure to TSA in IL-2
stimulated cells and returned to normal levels after 20
hours. In anti-CD3 stimulated cells MetAP2 was downreg-
ulated after 1 and 4 hours of exposure to TSA and was
upregulated after 20 hours. Expression of LAT (linker for
activation of T cells) was decreased after 4 hours of treat-
ment with TSA in IL-2 stimulated cells, returning to nor-
mal thereafter. In anti-CD3 stimulated cells however,
levels of LAT decreased already after 1 hour of exposure to
TSA and remained lower than in normal control cells up
to 20 hours of exposure to TSA. Levels of expression of the
tumor suppressor gene p16Ink4a were upregulated after 4
and 20 hours of treatment with TSA in IL-2 stimulated
cells but were essentially unaltered in anti-CD3 stimu-
lated cells. GATA-2, a zinc finger family transcription fac-
tor, was upregulated in IL-2 stimulated cells after 4 hours
of exposure to TSA but downregulated after 20 hours. In
anti-CD3 stimulated cells expression of GATA-2 was
upregulated after 1 hour of treatment with TSA and down-
regulated after 20 hours. Expression of CD28 (a
costimulatory molecule important for T cell activation)
was downregulated in both IL-2 and anti-CD3 stimulated
cells after 4 hours of exposure to TSA, but remained so
only in anti-CD3 stimulated cells after 20 hours. On the
other hand, upregulation of HMG14 (chromosomal pro-
tein) by TSA can only be observed in IL-2 stimulated cells
after 4 hours, remaining normal in anti-CD3 stimulated
cells. These data confirm the results obtained with the
microarray analysis and additionally show that the effects
of TSA are time and stimulus dependent.
One of the most consistent effects we observed with the
microarray analysis was the downregulation of several
subunits of the T cell receptor associated CD3 complex
(Figure 7A). Several subunits of this complex including
the ε chain are transcriptionally downregulated by TSA
treatment. To confirm this result and to determine how
the transcriptional effects translate into differences in pro-
tein expression and consequently functional effects, we
analyzed by flow cytometry the surface expression of the
CD3 molecular complex and CD3ε chain in IL-2 and anti-
CD3 stimulated CD4+ T cells, upon exposure to TSA for 4
and 20 hours (Figure 7C). As could be expected from the
microarray results, surface expression of CD3 decreased in
IL-2 stimulated cells after 20 hours and in anti-CD3 stim-
ulated after 4 and 20 hours exposure to TSA. These results
indicate that transcriptional modulation of genes by TSA
correlates into expression differences of molecules and
presumably into functional effects.
Discussion
HDAC inhibition is associated with growth arrest and cell 
death of T lymphocytes
Remodelling of chromatin structure of promoters is a key
mechanism in the regulation of gene expression in
eukaryotes. The pathogenic role of aberrant patterns of
gene expression in neoplastic transformation of cells
makes the HAT/HDAC enzymatic system an obvious tar-
get for therapeutic intervention. Even more so as several
reports link HAT/HDAC activity to cancer [51–53]. Cul-
turing of transformed cells in the presence of HDACIs
invariably leads to cell growth inhibition, and/or apop-
totic cell death, and in rodent models of cancer HDACIsBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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Transcriptional regulation of various genes by TSA Figure 7
Transcriptional regulation of various genes by TSA (A) Gene expression profile of TSA-treated and non-treated CD4+ 
T-cells. Naïve CD4+ CD62L+ CD44low cells were isolated from C57BL/6 spleen cell preparations, cultured in the presence of 
IL-2 (10 U/ml) for 24 hours and Atlas Mouse cDNA Expression Arrays were used to analyse the differential gene expression 
caused by exposure of these cells to 100 nM TSA for 4 hours. Shown are all genes that varied in expression by greater than 2-
fold in all experiments. Upward black arrows indicate upregulated genes, downward grey arrows denote downregulated genes. 
Data are based on two independent preparations of mRNA, for each experiment. Two membranes were used per sample. (B) 
Verification of several of the genes affected by TSA by semi-quantitative RT-PCR analysis. CD4+ T-cells were isolated by mag-
netic cell separation from pre-activated splenocytes (48 h in the presence of soluble anti-CD3 antibody). Cells were then stim-
ulated with immobilized anti-CD3 mAb or cultured in the presence of IL-2 (10 U/ml), and harvested after 1, 4, or 20 hours in 
the presence of 100 nM TSA. Expression of 18S rRNA was used as normalizing control (C) Flow cytometric analysis of CD3ε 
and CD3 MC (molecular complex) expression in CD4+ T-cells exposed to TSA. CD4+ T-cells were cultured in the presence of 
immobilized anti-CD3 antibody (2:1 beads to cells ratio) or IL-2 (10 U/ml) and exposed to 100 nM TSA for 4 hours (open black 
histogram) and 20 hours (bold open black histogram), or to DMSO alone for 4 hours (open grey histogram) or 20 hours (open 
bold grey histogram). Data are representative of three independent experiments.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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can significantly reduce the growth of tumors. Interest-
ingly, administration of several HDACIs at pharmacolog-
ically relevant doses shows no side effects, even on
embryonic development [16,54,55], a notable lack of
toxic effects from a class of anti-tumor drugs that induces
cell death and proliferation arrest in cultured cells. One
recent report provides an important clue as to the reason
of this differential effect; namely that normal cells are less
sensitive to HDAC inhibition than transformed counter-
parts [25]. However, non-transformed cells are also
affected by HDACIs and some reports have shown that T
cells are affected by HDACIs [21,38]. To try to understand
the mechanism(s) of preferential sensitivity of cancer cells
to HDAC inhibition and to determine if normal cells
might be affected by HDACIs to an extent that would
block their normal biological role, we decided to investi-
gate the effects of TSA on normal primary T cells using a
murine model system.
TSA is a first generation pharmacological compound,
which in a reversible and highly specific manner inhibits
histone deacetylases at nanomolar concentrations. The
high potency and specificity of this drug makes it a proto-
type compound and a very useful tool for studying the
effects of HDACIs. In this study we show that TSA induces
a reversible G1 cell cycle block, and apoptosis of prolifer-
ating T lymphocytes in a similar way to its effect on tumor
cells (Figure 1; panels A, B, C, and D) and at similar
concentrations.
Apoptosis is a strongly regulated molecular event with
two main pathways leading to apoptotic cell death. One
pathway involves interaction of a death receptor, such as
the TNF- or Fas-receptors with their respective ligands,
and the second is mitochondria-dependent. The end
result of either pathway is the activation of the caspase
cascade and the proteolytic processing of specific cellular
substrates, resulting in apoptotic cell death [56,57].
Here we demonstrate that the ability of TSA to induce cell
death is dependent upon de novo mRNA and protein syn-
thesis (Figure 2B) and intact mitochondrial function (Fig-
ure 2D). Induction of cell-death by TSA is apparently not
initiated through activation of the caspase cascade (Figure
2C) but rather by production of reactive oxygen species
(Figure 2E). Mitochondrial membrane damage seems to
be an important proapoptotic event in TSA-mediated T-
cell death as free radical scavengers and mitochondrial
respiration inhibitors significantly reduced TSA-induced
cytotoxicity (Figure 2F). In at least one reported situation,
HDACIs can also induce death receptor-mediated apop-
totic cell death [13]. This however, is apparently not the
case with TSA-induced T-cell death. In TSA-treated T cells
the levels of CD95 actually decrease, concomitant with
cell growth arrest, while the levels of CD95L increase only
very modestly (Figure 2D). Activation of the caspase path-
way and production of ROS in tumor cells has also been
reported for other HDACIs [13,28,30], suggesting that
HDACIs-specific alterations in gene expression result in
the generation of ROS and/or activation of the caspase
cascade with ensuing cell death. But if production of ROS
and caspase activation in response to transcriptional
events is a general cellular response to HDAC inhibition
why the preferential sensitivity of tumor cells? One possi-
bility is that a crucial subset of genes has to be deregulated
for cell death to occur.
In many cases, inhibition of cell growth by HDACIs has
been accompanied by transcriptional upregulation of the
cyclin-dependent inhibitors p27kip1 and p21cip1, leading to
the suggestion that these two genes might be key media-
tors of the HDACIs antiproliferative action. However,
mouse embryo fibroblasts deficient in both p27kip1 and
p21cip1 are also susceptible to cell cycle arrest by TSA [58].
Furthermore, there are several reports of synergistic inter-
actions between HDACIs and other compounds leading
to apoptotic cell death in conditions where neither per se
would have an effect [36,59]. These data indicate that
unlike other pharmacological agents whose effects are
dependent on targeting one key gene, or enzymatic activ-
ity, HDACIs affect several functionally unrelated genes
simultaneously, with the outcome being dependent on
the sum of cellular effects caused by the affected genes in
a given tissue or cell-type.
HDAC inhibition has immunomodulatory effects on T cells
In this study we demonstrate that exposure of CD4+ T-cells
to TSA decreases IL-2 mRNA levels (Figure 3B) abrogating
IL-2 production (Figures 3A and 3C). Abrogation of IL-2
production could contribute to induction of T-cell death
by HDAC inhibitors through IL-2 deprivation-induced
apoptosis. However, exogenous addition of IL-2 does not
significantly affect T-cell survival upon treatment with TSA
(Figure 4A), and neither does addition of other cytokines
(Figure 4B). These data indicate that the apoptotic path-
way induced by TSA cannot be rescued by external stimuli
such as cytokines, and activation signals such as anti-CD3
and anti-CD28 (Figure 4B).
Lymphocytes are typically exposed to various extracellular
stimuli such as growth factors and cytokines that activate
both cell survival and apoptotic pathways. NF-κB is a cen-
tral transcription factor in these responses [43,60,61].
Translocation of NFκB p65 from the cytoplasm to the
nucleus in PBMCs is inhibited by butyrate, an effect
apparently mediated by inhibition of IκB degradation
[46]. We examined the degradation pattern of IκBα in
response to a strong activation stimulus (PMA+ionomy-
cin) in T-cells that had been exposed to TSA (Figure 5B)
and could not observe an inhibitory effect of TSA on IκBαBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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degradation. Notwithstanding, the nuclei of CD4+ T-cells
treated with TSA displayed significantly lower levels of
NFκB as compared to a control population (Figure 5A).
Consequently, HDAC inhibition by TSA affects NFκB sig-
naling but not through an effect on IκBα degradation,
indicating that another mechanism is responsible for this
effect. Interestingly, a recent study showed that the p65
subunit of NFκB is subject to acetylation by both p300
and PCAF and can interact with HDAC2 and HDAC3 [62].
Furthermore, the authors show that acetylation reduces
binding of p65 to κB-containing DNA, facilitating its
removal by IκBα and subsequent export to the cytoplasm.
Thus, higher levels of acetylation of p65 due to HDAC
inhibition would probably result in increased nuclear
export and reduced binding affinity for cognate sites. The
pivotal role played by NFκB in T-cell survival and apopto-
sis suggests this transcription factor to be a mediator of
TSA-induced T cell death, and potentially of other effects
on gene expression as well.
Expression of a number of adhesion/costimulatory mole-
cules is deregulated by TSA treatment. As shown in Figure
6A, TSA affects expression of several markers not only in
CD4+ T-cells (Figure 6A; CD4+ T-cell) but also in other
lymphoid cells (Figure 6A; non-CD4). Interestingly, these
effects are extremely diverse in amplitude, time frame and
cell type. Hence, expression of the IL-2 receptor β chain
(IL-2Rβ) is upregulated by TSA after 4 hours of treatment
in CD4+ T-cells and non-CD4 cells if the cells are cultured
in the presence of IL-2, but not if the cells are stimulated
with anti-CD3 antibody. Conversely, after 20 hours of
treatment with TSA expression of IL-2Rβ is downregulated
both in CD4+ T-cells and non-CD4 cells. Other costimula-
tory molecules such as CD28 and CD80 are downregu-
lated by TSA independently of cell type, but in a stimulus
dependent manner, in that their expression is not affected
in cells stimulated with anti-CD3 antibody but declines in
the presence of IL-2. Other molecules are affected only in
a given set of conditions. One such case is the expression
of CD95/Fas. Expression of this cell surface receptor is
essentially unaffected by TSA in cells stimulated with anti-
CD3 antibody (either CD4+ T-cells or non-CD4 cells)
independently of time. However, after 20 hours of expo-
sure to TSA, IL-2 stimulated cells show down-regulation of
CD95/Fas with non-CD4 cells being the most affected.
One consequence of this differential sensitivity is that
exposure to TSA skews the composition of a cell popula-
tion, with different subpopulations being affected to dif-
ferent extents (Figure 6B).
A recent study on the effects of TSA in primary murine
macrophages showed that TSA inhibits CD9 protein and
message expression, resulting in a modest increase or no
effect on CD54 and CD11b, respectively [63]. In short,
TSA can up- as well as down-regulate expression of cell
surface molecules, and it does so in a time-, cell type- and
stimulus-dependent manner.
To further characterize the mechanism by which TSA
exerts its effects, we performed gene expression profiling
of 2352 known genes employing microarrays (Atlas
mouse 1.2 and 1.2 II; CLONTECH Laboratories, Inc.) and
show that genes involved in generating a full T-cell
response are affected by TSA (Figure 7A). Some of the
genes we identified in this manner are known targets for
HDACs, validating them as bona fide targets of TSA-medi-
ated HDAC inhibition in T cells. That is the case of Hsp70,
notch1 and 2, RARα, RARβ, and Stra13, among others
[55,64,65]. Additionally, many of the genes deregulated
by TSA play a crucial role in immune regulation. That is
the case of Notch-1 (important in controlling levels of cell
death in T cells); stra13 (a transcriptional repressor associ-
ated with cell cycle progression and cell growth); TGFβ1
(a cytokine involved in modulation of immune
responses); ICAM1 (adhesion molecule, can induce T cell
proliferation). It is also noteworthy that we identified a
TSA-responding subset of 48 genes out of a total of 2352
genes examined, which corresponds to roughly 2% of the
examined genes being affected by TSA. Several studies
have reported a similar figure (~2%) for other HDACIs
and cell types [10,11] demonstrating the specificity of
effects exerted by HDACIs. A time course RT-PCR analysis
of several gene targets shows that some effects of TSA are
transient (LAT; Figure 7B – IL-2 stimulated cells) others
are stimulus dependent (HMG14, MetAP2; Figure 7B – IL-
2 versus anti-CD3) underscoring the regulatory complex-
ity of chromatin structure-mediated gene regulation.
The cell-type, time and stimulus dependency of the TSA-
mediated transcriptional effects we observed, shed some
light on the multitude of effects, sometimes contradictory,
seen with HDACIs in a variety of studies. Previously
reported data suggest that HDACs may regulate zygotic/
embryonic gene expression and are essential for proper
embryonic development, whereas other studies show that
the effects of HDACIs on transcription do not result in
teratogenesis [55,66–68]. Expression of IL-2 and IFNγ can
also be affected in opposite manners. Hence, treatment of
T cells with TSA leads to increased production of IFNγ
[21,69] whereas exposure to SAHA inhibits IFNγ produc-
tion [38]. Similarly, TSA abrogates IL-2 production in
human leukemic Jurkat T cells and primary T-lym-
phocytes ([19] and this study) but it causes an increase in
IL-2 transcription in EL-4 thymoma T cells [70]. In short,
we show that HDACIs affect gene expression with exqui-
site specificity, not only at the gene level but also in a time,
cell-type and stimulus dependent manner. HDACs play a
significant role in the regulation of genes important for T
cell modulationBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/30
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In peripheral blood mononuclear cells (PBMCs), activa-
tion by PHA, PMA and anti-CD3 increases HDAC mRNA
levels suggesting that HDACs are involved in cell cycle
progression and activation [71]. We show in this study
that TSA affects many genes involved in generating a full
T cell response and that the effects of TSA on T-cells are
predominantly immunosuppressive indicating that HDA-
CIs may represent a novel approach to the control of
inflammation.
Conclusions
Remodelling of chromatin structure of promoters is a key
mechanism in the regulation of gene expression in
eukaryotes. The pathogenic role of aberrant patterns of
gene expression in neoplastic transformation of cells
makes the HAT/HDAC enzymatic system an obvious tar-
get for therapeutic intervention. Even more so as several
reports link HAT/HDAC activity to cancer. Due to their
growth-inhibiting and differentiation-inducing proper-
ties, HDACIs are the object of intensive research. The
remarkable tumor specificity of these compounds
together with strikingly few side effects contribute to make
HDACIs an exciting new therapeutic approach to cancer.
One recent report provides an important clue as to the rea-
son of this differential effect; namely that normal cells are
less sensitive to HDAC inhibition than transformed coun-
terparts. But several problems still need to be addressed
and a number of discrepant observations clarified. Exper-
iments with HDACIs in animal model systems support a
preferential effect of these drugs on tumor cells but do not
exclude the possibility that particularly sensitive non-
malignant cell types might exist. Our results clearly dem-
onstrate that normal primary CD4+ T cells are sensitive to
HDACIs. The cytotoxic effect of TSA was dose dependent
and dependent on the generation of reactive oxygen spe-
cies. We also demonstrate that various cellular functions,
such as proliferation and cytokine production, were
inhibited when T cells were exposed to TSA. Interestingly,
expression of a subset of genes involved in T cell
responses, including a variety of costimulatory/adhesion
molecules, was reduced in cells treated with TSA. Briefly,
our findings show that HDACIs have a strong immu-
nomodulatory potential that may contribute to the
potency and specificity of these antineoplastic com-
pounds and suggest that the immunosuppressive vs.
increased tumor immunity effect of HDACIs might be
important for targeting tumor cell proliferation and sur-
vival, which may impinge on the future clinical use of
these drugs.
Another aim of our study was to evaluate the cellular
mechanisms by which HDACIs function, the current view
being that HDAC inhibitors, such as Trichostatin A (TSA),
induce hyperacetylation of core histones modulating
chromatin structure and affecting gene expression. Even
so, global histone hyperacetylation does not lead to a gen-
eralized increase in transcription but rather to deregula-
tion of a limited set of, suggesting that chromatin
structure modulation by HDACs is a gene-specific event
with a variable transcriptional outcome, and that only a
few genes (approximately 2%) are regulated primarily
through HDAC-dependent mechanisms. Even though
several genes modulated by HDAC inhibition have been
identified, those genes clearly responsible for the biologi-
cal effects of these drugs have remained elusive. Our
microarray analysis of T-cells exposed to TSA showed that
about 2% of the examined genes were deregulated. Inter-
estingly, the extent of the effects caused by TSA varied with
time and the stimuli applied to cells, indicating that a
complex set of interactions is at work. But if only a limited
number of genes are deregulated by HDACIs, with no sin-
gle gene being incontrovertibly responsible for the com-
pound's biological effects, how can one explain the
myriad of cellular effects that histone deacetylase inhibi-
tors can bring about? The answer might be that a
misleading notion is the culprit for the elusiveness of the
mechanism of action of HDACIs. Originally identified as
the enzymes responsible for the removal of acetyl groups
from histones, histone deacetylases have remained
known as such even though we now know that they can
function as deacetylase activities on proteins other than
histones. An emerging body of literature supports a role
for acetylation in regulating protein function and several
proteins, including many with cancer relevance such as
p53, NF-κB, c-Myb, PR, GATA-1, E2F-1, -2, and -3, have
been identified as targets for acetylases. Thus, modulation
of protein function by acetylation might be one of the pri-
mary molecular mechanisms by which HDACIs exert their
biological effects. One could then envision the physiolog-
ical and therapeutic effects of these compounds as the
end-result of their combined biological effects. Blocking
deacetylase(s) activity will not only result in global his-
tone hyperacetylation and concomitant transcriptional
derepression but also lead to increased acetylation of non-
histone proteins. These can be transcription factors such
as p53 and NF-κB, structural proteins like tubulin, or any
other type of protein. Increased acetylation of these pro-
teins will result in altered activity (e.g. localisation of
nuclear NF-κB is dependent on acetylation levels) and
consequently in an altered biological state. Effects result-
ant from altered protein function in addition to those
resulting from global hyperacetylation and derepression
of gene expression, adds a new level of complexity to the
mechanism(s) of action of HDACIs and explains several
answered questions that the simpler histone-only model
could not easily explain.
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